Kinoxis Therapeutics launched to develop anti-addiction drugs
Some $3.9 million has been raised in an initial financing round to develop novel anti-addiction compounds. SOC-1, which will progress through pre-clinical testing, mimics the properties of the "pleasure hormone" oxytocin.